Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA System
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Post Operative Pain
Conditions
Post Operative Pain
Trial Timeline
Aug 1, 2012 → May 1, 2013
NCT ID
NCT01660763About Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA System
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA System is a phase 3 stage product being developed by Talphera for Post Operative Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT01660763. Target conditions include Post Operative Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01660763 | Phase 3 | Completed |
| NCT01539642 | Phase 3 | Completed |
Competing Products
20 competing products in Post Operative Pain